After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
The group eyes a broader use than Immunocore’s Kimmtrak.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
